Polymyositis
Evidence-based neurology checklist on polymyositis: Epidemiological features The onset is typically after the of age 16 years The onset may be triggered by TNF-𝛼 blocking agents Neurological features Cardiac features Neoplastic features Differential diagnosis
Epidemiological features
- The onset is typically after the of age 16 years
- The onset may be triggered by TNF-𝛼 blocking agents
Neurological features
Cardiac features
Neoplastic features
Differential diagnosis
References
- Dalakas MC. Therapeutic advances and future prospects in immune-mediated inflammatory myopathies. Ther Adv Neurol Disord 2008; 1:157-166.
- Rendt K. Inflammatory myopathies: narrowing the differential diagnosis. Cleve Clin J Med 2001; 68:505-519.
- Brunasso AMG, Aberer W, Massone C. New onset of dermatomyositis/polymyositis during anti-TNF-𝛼 therapies: a systematic literature review. ScientificWorldJournal 2014; 2014:179180.
- Prasad K, Behari M, Maheshwari MC. Muscle hypertrophy in chronic polymyositis. JNNP 1985 48:1309.
- Kesserwani H. Predominant neck extensor muscle weakness: a rare manifestation of idiopathic polymyositis. Cureus 2020; 12:e8735.
- And 6 more. Subscribe to see the full list
